Chinese patients’ preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment

Lei Si, Liudan Tu, Ya Xie, Andrew Palmer, Yuanyuan Gu, Xuqi Zheng, Jiamin Li, Qing Lv, Jun Qi, Zhiming Lin, Mingsheng Chen, Jieruo Gu, Mickaël Hiligsmann

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Summary: While adherence to osteoporosis treatment is low, patients’ preference for osteoporosis treatment is unknown in Chinese patients. Chinese patients are willing to receive treatments with higher clinical efficacy and lower out-of-pocket cost. In addition, annual intravenous infusion and 6-month subcutaneous injection are preferred over weekly oral tablets. Purpose: This study was performed to elicit Chinese patients’ preferences for osteoporosis medication treatment and to investigate the heterogeneities of the preferences in subgroups. Methods: A discrete choice experiment comprising 15 choice sets with 4 important attributes was conducted in a Chinese population at risk of osteoporotic fracture. The four attributes were treatment efficacy in reducing the risk of fracture, out-of-pocket cost per year, adverse effects of treatment, and mode of administration. The patients were asked to choose between two hypothetical treatments; they could also choose no treatment. Mixed logit models were used, and any observed heterogeneity in the patients’ preferences was further assessed in subgroup analyses. Results: In total, 267 patients were analysed. On average, the patients preferred to receive treatment rather than no treatment. The patients preferred treatment with higher efficacy in preventing fracture and lower out-of-pocket cost. The least preferred adverse effect of medication was gastrointestinal disorders, followed by flu-like symptoms and finally skin reactions. The most preferred mode of administration was annual intravenous infusion, followed by 6-month subcutaneous injection, a weekly oral tablet, and daily nasal spray; daily oral tablets ranked as the least preferred mode of administration. The differences in the patients’ preferences among all attributes were statistically significant (p < 0.05). Patients’ age was found to contribute to the observed preference heterogeneity in most of the included attributes. Conclusions: This study revealed Chinese patients’ preferences for osteoporosis treatments. Annual intravenous infusion and 6-month subcutaneous injection were significantly preferred over weekly oral tablets in this Chinese population.

LanguageEnglish
Article number85
Number of pages9
JournalArchives of Osteoporosis
Volume14
Issue number1
DOIs
Publication statusPublished - Dec 2019

Fingerprint

Patient Preference
Osteoporosis
Pharmaceutical Preparations
Tablets
Subcutaneous Injections
Health Expenditures
Intravenous Infusions
Therapeutics
Nasal Sprays
Osteoporotic Fractures
Logistic Models

Cite this

Si, Lei ; Tu, Liudan ; Xie, Ya ; Palmer, Andrew ; Gu, Yuanyuan ; Zheng, Xuqi ; Li, Jiamin ; Lv, Qing ; Qi, Jun ; Lin, Zhiming ; Chen, Mingsheng ; Gu, Jieruo ; Hiligsmann, Mickaël. / Chinese patients’ preference for pharmaceutical treatments of osteoporosis : a discrete choice experiment. In: Archives of Osteoporosis. 2019 ; Vol. 14, No. 1.
@article{479cdb4f31a14b6d95d1af8ab178dfeb,
title = "Chinese patients’ preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment",
abstract = "Summary: While adherence to osteoporosis treatment is low, patients’ preference for osteoporosis treatment is unknown in Chinese patients. Chinese patients are willing to receive treatments with higher clinical efficacy and lower out-of-pocket cost. In addition, annual intravenous infusion and 6-month subcutaneous injection are preferred over weekly oral tablets. Purpose: This study was performed to elicit Chinese patients’ preferences for osteoporosis medication treatment and to investigate the heterogeneities of the preferences in subgroups. Methods: A discrete choice experiment comprising 15 choice sets with 4 important attributes was conducted in a Chinese population at risk of osteoporotic fracture. The four attributes were treatment efficacy in reducing the risk of fracture, out-of-pocket cost per year, adverse effects of treatment, and mode of administration. The patients were asked to choose between two hypothetical treatments; they could also choose no treatment. Mixed logit models were used, and any observed heterogeneity in the patients’ preferences was further assessed in subgroup analyses. Results: In total, 267 patients were analysed. On average, the patients preferred to receive treatment rather than no treatment. The patients preferred treatment with higher efficacy in preventing fracture and lower out-of-pocket cost. The least preferred adverse effect of medication was gastrointestinal disorders, followed by flu-like symptoms and finally skin reactions. The most preferred mode of administration was annual intravenous infusion, followed by 6-month subcutaneous injection, a weekly oral tablet, and daily nasal spray; daily oral tablets ranked as the least preferred mode of administration. The differences in the patients’ preferences among all attributes were statistically significant (p < 0.05). Patients’ age was found to contribute to the observed preference heterogeneity in most of the included attributes. Conclusions: This study revealed Chinese patients’ preferences for osteoporosis treatments. Annual intravenous infusion and 6-month subcutaneous injection were significantly preferred over weekly oral tablets in this Chinese population.",
keywords = "Discrete choice experiment, Pharmaceutical treatment, Osteoporosis, Patient preferences, Chinese",
author = "Lei Si and Liudan Tu and Ya Xie and Andrew Palmer and Yuanyuan Gu and Xuqi Zheng and Jiamin Li and Qing Lv and Jun Qi and Zhiming Lin and Mingsheng Chen and Jieruo Gu and Micka{\"e}l Hiligsmann",
year = "2019",
month = "12",
doi = "10.1007/s11657-019-0624-z",
language = "English",
volume = "14",
journal = "Archives of Osteoporosis",
issn = "1862-3522",
publisher = "Springer, Springer Nature",
number = "1",

}

Si, L, Tu, L, Xie, Y, Palmer, A, Gu, Y, Zheng, X, Li, J, Lv, Q, Qi, J, Lin, Z, Chen, M, Gu, J & Hiligsmann, M 2019, 'Chinese patients’ preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment' Archives of Osteoporosis, vol. 14, no. 1, 85. https://doi.org/10.1007/s11657-019-0624-z

Chinese patients’ preference for pharmaceutical treatments of osteoporosis : a discrete choice experiment. / Si, Lei; Tu, Liudan; Xie, Ya; Palmer, Andrew; Gu, Yuanyuan; Zheng, Xuqi; Li, Jiamin; Lv, Qing; Qi, Jun; Lin, Zhiming; Chen, Mingsheng; Gu, Jieruo; Hiligsmann, Mickaël.

In: Archives of Osteoporosis, Vol. 14, No. 1, 85, 12.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Chinese patients’ preference for pharmaceutical treatments of osteoporosis

T2 - Archives of Osteoporosis

AU - Si,Lei

AU - Tu,Liudan

AU - Xie,Ya

AU - Palmer,Andrew

AU - Gu,Yuanyuan

AU - Zheng,Xuqi

AU - Li,Jiamin

AU - Lv,Qing

AU - Qi,Jun

AU - Lin,Zhiming

AU - Chen,Mingsheng

AU - Gu,Jieruo

AU - Hiligsmann,Mickaël

PY - 2019/12

Y1 - 2019/12

N2 - Summary: While adherence to osteoporosis treatment is low, patients’ preference for osteoporosis treatment is unknown in Chinese patients. Chinese patients are willing to receive treatments with higher clinical efficacy and lower out-of-pocket cost. In addition, annual intravenous infusion and 6-month subcutaneous injection are preferred over weekly oral tablets. Purpose: This study was performed to elicit Chinese patients’ preferences for osteoporosis medication treatment and to investigate the heterogeneities of the preferences in subgroups. Methods: A discrete choice experiment comprising 15 choice sets with 4 important attributes was conducted in a Chinese population at risk of osteoporotic fracture. The four attributes were treatment efficacy in reducing the risk of fracture, out-of-pocket cost per year, adverse effects of treatment, and mode of administration. The patients were asked to choose between two hypothetical treatments; they could also choose no treatment. Mixed logit models were used, and any observed heterogeneity in the patients’ preferences was further assessed in subgroup analyses. Results: In total, 267 patients were analysed. On average, the patients preferred to receive treatment rather than no treatment. The patients preferred treatment with higher efficacy in preventing fracture and lower out-of-pocket cost. The least preferred adverse effect of medication was gastrointestinal disorders, followed by flu-like symptoms and finally skin reactions. The most preferred mode of administration was annual intravenous infusion, followed by 6-month subcutaneous injection, a weekly oral tablet, and daily nasal spray; daily oral tablets ranked as the least preferred mode of administration. The differences in the patients’ preferences among all attributes were statistically significant (p < 0.05). Patients’ age was found to contribute to the observed preference heterogeneity in most of the included attributes. Conclusions: This study revealed Chinese patients’ preferences for osteoporosis treatments. Annual intravenous infusion and 6-month subcutaneous injection were significantly preferred over weekly oral tablets in this Chinese population.

AB - Summary: While adherence to osteoporosis treatment is low, patients’ preference for osteoporosis treatment is unknown in Chinese patients. Chinese patients are willing to receive treatments with higher clinical efficacy and lower out-of-pocket cost. In addition, annual intravenous infusion and 6-month subcutaneous injection are preferred over weekly oral tablets. Purpose: This study was performed to elicit Chinese patients’ preferences for osteoporosis medication treatment and to investigate the heterogeneities of the preferences in subgroups. Methods: A discrete choice experiment comprising 15 choice sets with 4 important attributes was conducted in a Chinese population at risk of osteoporotic fracture. The four attributes were treatment efficacy in reducing the risk of fracture, out-of-pocket cost per year, adverse effects of treatment, and mode of administration. The patients were asked to choose between two hypothetical treatments; they could also choose no treatment. Mixed logit models were used, and any observed heterogeneity in the patients’ preferences was further assessed in subgroup analyses. Results: In total, 267 patients were analysed. On average, the patients preferred to receive treatment rather than no treatment. The patients preferred treatment with higher efficacy in preventing fracture and lower out-of-pocket cost. The least preferred adverse effect of medication was gastrointestinal disorders, followed by flu-like symptoms and finally skin reactions. The most preferred mode of administration was annual intravenous infusion, followed by 6-month subcutaneous injection, a weekly oral tablet, and daily nasal spray; daily oral tablets ranked as the least preferred mode of administration. The differences in the patients’ preferences among all attributes were statistically significant (p < 0.05). Patients’ age was found to contribute to the observed preference heterogeneity in most of the included attributes. Conclusions: This study revealed Chinese patients’ preferences for osteoporosis treatments. Annual intravenous infusion and 6-month subcutaneous injection were significantly preferred over weekly oral tablets in this Chinese population.

KW - Discrete choice experiment

KW - Pharmaceutical treatment

KW - Osteoporosis

KW - Patient preferences

KW - Chinese

UR - http://www.scopus.com/inward/record.url?scp=85069988210&partnerID=8YFLogxK

U2 - 10.1007/s11657-019-0624-z

DO - 10.1007/s11657-019-0624-z

M3 - Article

VL - 14

JO - Archives of Osteoporosis

JF - Archives of Osteoporosis

SN - 1862-3522

IS - 1

M1 - 85

ER -